2.5-year-old's limp uncovers osteosarcoma — a limb-saving care path

The first clinically useful signal in this case came not from a specialist but from a daycare worker who noticed a two-and-a-half-year-old dragging one side after a minor fall. For health systems and care teams, Mileah's journey is a live case study in why persistent pediatric limb complaints warrant structured follow-up and early imaging — and why the payoff is a limb-salvage surgery that can preserve a child's long-term mobility.

The key development is a pediatric oncology case from Sydney in which a subtle gait abnormality — what mother Kelly Hennessy first dismissed as her two-and-a-half-year-old daughter Mileah mimicking an older cousin's 'weird, long-legged skip' — proved to be osteosarcoma, a rare and aggressive primary bone cancer. The path from a daycare observation to a confirmed diagnosis and major reconstructive surgery lays bare both the diagnostic difficulty of childhood bone tumors and the intensive, multidisciplinary treatment required to preserve life and limb.

“

The chemotherapy backbone for osteosarcoma — built around doxorubicin with high-dose methotrexate and cisplatin in the MAP regimen — was established in the 1970s and 1980s and has changed little since.

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, but it is nonetheless rare, accounting for only a small fraction of childhood cancers, with peak incidence during the adolescent growth spurt. A diagnosis at age two-and-a-half is unusually early, which is precisely why the tumor's presentation was easy to miss. The case unfolded when daycare staff reported Mileah was dragging one side after a minor fall. Her mother initially suspected a sprain, but an X-ray revealed a large dark mass around the left knee and femur, and a pediatrician framed the differential as infection versus tumor. The first biopsy was inconclusive, and it took roughly two weeks for a second biopsy to confirm osteosarcoma — a window of uncertainty that is common in pediatric sarcoma workups and that places enormous psychological strain on families.

Once diagnosed, Mileah's treatment followed the broad contours of modern osteosarcoma management: systemic chemotherapy before surgery, followed by definitive local control. Within days she had a central line placed and began chemotherapy including doxorubicin, the anthracycline widely known as the 'red devil' for its crimson color and formidable toxicity. Her course was complicated by the hallmark toxicities of intensive pediatric regimens — fevers, vomiting, mucositis, and repeated hospitalizations for infection — underscoring that survival in pediatric osteosarcoma is bought at a heavy price in acute morbidity and supportive-care burden.

After two cycles of chemotherapy, Mileah underwent a Van Ness rotationplasty, a limb-salvage procedure most often chosen for very young children with tumors around the knee. In rotationplasty, the diseased portion of the leg — including the knee joint and lower femur — is resected, and the remaining lower leg and ankle are rotated 180 degrees and reattached so that the ankle functions as a new knee, with the foot fitting into a below-knee-style prosthesis. For a child of Mileah's age, this approach offers durable, high-functioning outcomes: the preserved ankle joint provides an active knee-like hinge, the foot acts as a biological shock absorber, and the child can run and play in a way that is often more athletic than with a standard above-knee amputation. Amputation above the knee had been raised as a possibility given Mileah's young age and the tumor's position, and the choice of rotationplasty reflects a pediatric-surgical philosophy that prioritizes long-term function over cosmetic simplicity.

For healthcare systems and clinicians, the case is a reminder that the earliest signal of pediatric bone cancer is often a nonspecific limp or limb complaint reported by non-clinicians — parents, daycare workers, teachers. Structured follow-up of persistent pediatric limb symptoms and a low threshold for imaging in the right clinical context remain the most practical early-detection tools, because no screening test exists for osteosarcoma.